Tempest Therapeutics Announces Option to License In Vivo CAR‑T Technology

What Happened
On September 14, 2026, Tempest Therapeutics, Inc. announced an exclusive collaboration, option and license agreement with Heibei Senlang Biotechnology Co., Ltd. Senlang granted Tempest an exclusive option, exercisable within four months (by January 14, 2027), to obtain an exclusive, royalty‑bearing, sublicensable license to develop and commercialize Senlang’s in vivo CAR‑T technology worldwide excluding Greater China. Tempest issued a related press release on September 15, 2026.

Key Details

• Option exercise fee of approximately $447,000 to obtain the license.
• Annual maintenance fees on the license escalate from $10 million to $14 million over the first three years (Tempest may elect to stop paying, with corresponding reductions to development timelines).
• Royalty rate of 6% on net sales plus a share of any sublicense revenue; nomination fees and IND/business‑development milestone obligations also apply.
• Each party has a right of first negotiation for Greater China rights; agreement includes customary termination rights (material breach, bankruptcy, patent challenges by Tempest, and Tempest’s termination for convenience on 90 days’ notice).

Why It Matters
The agreement gives Tempest a time‑limited option to secure exclusive global (excluding Greater China) rights to an in vivo CAR‑T platform, potentially expanding its therapeutic platform and pipeline. Exercising the option would create meaningful ongoing financial obligations (multi‑million annual fees and royalties) and development/milestone commitments that investors should consider when assessing potential future costs and upside.